Christopher  Plowe
 

Christopher Plowe M.D., M.P.H.

Academic Title: Professor
Primary Appointment: Medicine
Secondary Appointments: Epidemiology and Preventive Medicine, Microbiology and Immunology
Additional Title(s): Chief, Malaria Section; Doris Duke Distinguished Clinical Scientist; Investigator, Howard Hughes Medical Institute
cplowe@medicine.umaryland.edu
Location: HSF1, Room 480
Phone: (410) 706-2491
Phone: (410) 706-3082
Fax: (410) 706-1204
Lab: (410) 706-5932

Personal History

Christopher Plowe is Professor of Medicine, of Microbiology and Immunology, and of Epidemiology and Preventive Medicine at the University of Maryland School of Medicine. He is Chief of the Malaria Section of the University's Center for Vaccine Development. Dr. Plowe received his B.A. in Philosophy from Cornell University in 1982, an M.D. from Cornell University Medical College in 1986, and an M.P.H. in Tropical Medicine from Columbia University School of Public Health in 1991. He completed an internship and residency in Internal Medicine and was Chief Medical Resident at St. Luke's Hospital of Columbia College of Physicians and Surgeons in New York, New York, and completed fellowships in malaria research at the National Institutes of Health and in Infectious Diseases at Johns Hopkins University School of Medicine in Baltimore, Maryland before joining the faculty of the University of Maryland's Center for Vaccine Development in 1995. He has received a Doris Duke Distinguished Clinical Scientist Award and the Bailey K. Ashford Medal for distinguished work in tropical medicine from the American Society of Tropical Medicine and Hygiene. In 2007 he was selected as a Howard Hughes Medical Institute Investigator in Patient-Oriented Research.

Research Interests

In the Malaria Section we work on malaria drug resistance, molecular epidemiology, molecular evolution, pathogenesis, HIV-malaria interactions and clinical trials of malaria drugs and vaccines. We do laboratory and field research on the molecular mechanisms and molecular epidemiology of resistance to antimalarial drugs, particularly the antifolate drugs and chloroquine. Plasmodium falciparum malaria resistant to these drugs is already widespread in much of South America and Asia, and chloroquine resistance is responsible for large increases in malaria morbidity and mortality in Africa. Our team has developed rapid molecular assays for parasite mutations that cause the parasite to be resistant to specific drugs for use as public health tools for monitoring resistance in malaria-endemic areas. In collaboration with colleagues at the University of Mali, we have developed a field research site in the Dogon Country of Mali. This field station is the site of studies of drug resistance, pathogenesis and immunology of severe malaria, and clinical trials of malaria vaccines. In Malawi we work on clinical trials of malaria drugs, molecular epidemiology of drug resistant malaria and the impact of antimicrobial use on antimalarial drug resistance in persons living with HIV. We recently reported that chloroquine sensitive malaria had returned to Malawi 12 years after chloroquine was withdrawn. At the Center for Vaccine Development in Baltimore, we study the impact of genetic diversity on malaria drug and vaccine efficacy using high-throughput genotyping and mathematical modeling. We work with scientists in Africa, Asia and South America to train junior scientists and build research capacity in malaria-endemic countries.

Clinical Speciality

Tropical Medicine and Travelers' Health

Publications

Most Recent Publications

Dzinjalamala F, Macheso A, Kublin J, Taylor T, Barnes K, Molyneux M, Plowe C, Smith P. Blood folate concentrations and in vivo sulfadoxine-pyrimethamine failure in Malawian children with uncomplicated malaria. American Journal of Tropical Medicine and Hygiene. 72:267-272, 2005.

Diallo D, Doumbo O, Plowe C, Wellems T, Emanuel E, Hurst S. Community permission for medical research in developing countries. Clinical Infectious Diseases. 41:255-259, 2005.

van Oosterhout J, Laufer M, Graham S, Thumba F, Perez M, Chimbiya N, Wilson L, Chagomerana M, Molyneux M, Zijlstra E, Taylor T, Plowe C. A community-based study of the incidence of trimethoprim-sulfamethoxazole-preventable infections in Malawian adults living with HIV. Journal of Acquired Immune Deficiency Syndrome. 39:626-631, 2005.

Lyke K, Burges R, Cissoko, Y, Sangare L, Kone A, Fernandez-Vina M, Plowe C, Doumbo O, Sztein M. HLA-A2 supertype-restricted cell-mediated immunity by peripheral blood mononuclear cells derived from Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls. Infection and Immunity. 73:5799-5808, 2005.

Dzinjalamala F, Macheso A, Kublin J, Taylor T, Barnes K Molyneux M, Plowe C, Smith P. Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children. Antimicrobial Agents & Chemotherapy. 49:3601-3606, 2005.

Thera M, Sehdev P, Coulibaly D, Traore K, Garba M, Cissoko Y, Kone A, Guindo A, Dicko A, Beavogui A Djimde A, Lyke K, Diallo D, Doumbo O, Plowe C. Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. Journal of Infectious Diseases,192:1823-1829, 2005.

Lyke K, Dicko A, Dabo A, Sangare L, Kone A, Coulibaly D, Guindo A, Traore K, Daou M, Diarra I, Sztein M, Plowe C, Doumbo O. Association of Schistosoma haematobium infection with protection against acute Plasmodium falciparum malaria in Malian children. American Journal of Tropical Medicine and Hygiene. 73:1124-1130, 2005.

Laufer M, van Oosterhout J, Thesing P, Thumba F, Zijlstra E, Taylor T, Plowe C. Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi. Journal of Infectious Diseases. In press, 2006.

Laufer MK, van Oosterhout J, Thesing P, Thumba F, Zijlstra E, Graham S, Taylor T, Plowe CV. Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi. Journal of Infectious Diseases 193:872-878, 2006.

Takala SL, Smith D, Stine O, Coulibaly D, Thera M, Doumbo O, Plowe CV. A high-throughput method for quantifying alleles and haplotypes of the malaria vaccine candidate Plasmodium falciparum merozoite surface protein-1 19kDa. Malaria Journal 5:31, 2006.

Mendez F, Munoz A, Plowe CV. Use of area under the curve to characterize transmission potential after antimalarial treatment. American Journal of Tropical Medicine and Hygiene 75:640-644, 2006.

Laufer MK, Thesing PC, Eddington N, Masonga R, Dzinjalamala F, Takala SL, Taylor T, Plowe CV. Return of chloroquine anti-malaria efficacy in Malawi. New England Journal of Medicine 355:1959-1966, 2006.

Thera T, Doumbo OK, Coulibaly D, Diallo D, Sagara I, Dicko A, Diemert D, Heppner Jr. DG, Stewart V, Angov E, Soisson L, Leach A, Tucker K, Lyke KE, Plowe CV and the Mali FMP1 Working Group. Randomized, double-blind controlled trial of the safety and allele-specific immunogenicity of the Plasmodium falciparum merozoite surface protein-142/AS02A malaria vaccine in Malian adults exposed to intense seasonal malaria. PLoS Clinical Trials 1:e34, 2006.

Takala SL, Coulibaly D, Thera M, Dicko A, Smith D, Guindo A, Kone A, Ouattara A, Djimde A, Sehdev P. Lyke K, Diallo D, Doumbo OK, Plowe CV. Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. PLoS Medicine 4:e93, 2007.

Takala SL, Smith D, Thera M, Coulibaly D, Doumbo OK, Plowe CV. Rare Plasmodium falciparum merozoite surface protein 1 19KDA (MSP119) haplotypes identified in Mali using high-throughput genotyping methods. American Journal of Tropical Medicine and Hygiene 76:855-859, 2007.

Mendez F, Herrera S, Murrain B, Gutierrez A, Moreno LA, Manzano M, Munoz A, Plowe CV. Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to Anopheles mosquitoes. American Journal of Tropical Medicine and Hygiene 77:438-443, 2007.

Laufer MK, van Oosterhout JJ, Thesing PC, Dzinjalamala FK, Hsi T, Beraho L, Graham SM, Taylor TE, Plowe CV. Malaria treatment efficacy among people living with HIV: the role of host and parasite factors. American Journal of Tropical Medicine and Hygiene 77:627-632, 2007.

Laufer MK, Plowe CV. The interaction between HIV and malaria in Africa. Current Infectious Disease Reports 9:47-54, 2007.

Nyunt MM, Plowe CV. Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance. Clinical Pharmacology and Therapeutics 82:601-605, 2007.

Sibley CH, Barnes KI, Plowe CV. The rationale and plan for creating a World Antimalarial Resistance Network (WARN). Malaria Journal 6:118, 2007.

Plowe CV, Roper C, Barnwell JW, Happi CT, Joshi HH, Mbacham W, Meshnick SR, Mugittu K, Naidoo I, Price RN, Shafer RW, Sibley CH, Sutherland CJ, Zimmerman PA, Rosenthal PJ. World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malaria Journal 6:121, 2007.




Faculty members: Click here to update your contact information and create a profile.


This site will work and look much better in a modern web browser, such as Internet Explorer 6, Firefox, or Safari 1.2 (Mac)
© University of Maryland School of Medicine